<DOC>
	<DOCNO>NCT01995604</DOCNO>
	<brief_summary>The purpose study evaluate efficacy dHACM ( Dehydrated Human Amnion Chorion Membrane ) reduce time heal use post-laser recovery follow ActiveFX™ DeepFx™ fractionate ablative CO2 laser resurface face .</brief_summary>
	<brief_title>Dehydrated Human Amnion/Chorion Membrane ( dHACM ) Recovery After Fractionated Ablative CO2 Laser Resurfacing Face</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Male female subject good general health great 18 year age 2 . Must willing agree term protocol provide complete sign informed consent , HIPAA photography release form 3 . Subjects plan undergo fractionate ablative CO2 laser resurface full face 4 . Subject either Fitzpatrick Skin Types I , II III For female subject childbearing potential , must regular menstrual cycle prior study entry willing use acceptable form birth control entire course study . All systemic birth control measure must consistent use least 30 day prior entry study . A female consider NOT childbearing potential postmenopausal least one ( 1 ) year , without uterus and/or ovary , bilateral tubal ligation . Acceptable method birth control : oral contraceptive , contraceptive patches/rings/implants Norplant , DepoProvera , doublebarrier method ( e.g . condom spermicide ) , abstinence vasectomy partner . 5 . Negative urine pregnancy test result time study entry female childbearing potential , applicable 6 . Must willing comply study instruction complete entire course study 1 . Any uncontrolled systemic disease yet stabilize least one ( 1 ) year 2 . A significant history current evidence medical , psychological disorder , investigator 's opinion , would interfere objective study 3 . Recently excessive exposure sunlight artificial UV light ( e.g . : use tan beds/booths and/or sunbathe ) expectation tan time study use selftanner within 7 day study entry 4 . History presence skin condition/disease might interfere diagnosis evaluation study parameter ( i.e. , atopic dermatitis , eczema , psoriasis , seborrheic dermatitis ) 5 . Active bacterial , fungal , viral infection 6 . History Herpes Simplex Virus facial and/or perioral area 7 . Known allergy sensitivity benzocaine , lidocaine , tetracaine , PABA ( paraaminobenzoic acid ) , local anesthetic amide ester family 8 . Known allergy gentamicin and/or streptomycin 9 . Receiving topical product contain alphahydroxy acid , salicylic acid , Vitamins C E ( include derivative Vitamins C E ) face within 14 day prior study period , ingredient study product 10 . Receiving and/or microdermabrasion ( light medium skin peel ) treatment face within 30 day prior study period 11 . Using topical tretinoin product derivative face within 12 week prior study period 12 . Receiving chemical peel , systemic steroid , nonablative laser , light radio frequency treatment and/or Dermabrasion ( deep skin peel ) ablative laser treatment face must discontinue drug/treatment and/or procedure least 3 month prior enter study 13 . History keloid hypertrophic scar 14 . Use systemic retinoids , prescription overthecounter grade within past year 15 . A female subject pregnant , nurse infant planning pregnancy study 16 . Current participation complete participation clinical research study investigational drug device within 30 day prior start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>